However, other experimental evidence has shown a protective effect of RAAS inhibition in COVID‐19 patients,47 and, in a recent retrospective clinical study, the use of ACE inhibitors and ARBs was associated with lower overall mortality among hospitalised COVID‐19 patients with hypertension.48 This evidence concerns the gene ACE and Hypertension.